Dose‐dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events
Open Access
- 13 June 2015
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 118 (2) , 221-229
- https://doi.org/10.1111/bju.13203
Abstract
Objectives To investigate the dose‐dependent effect of androgen deprivation therapy (ADT) on adverse cardiac events in elderly men with non‐metastatic prostate cancer (PCa) stratified according to life expectancy. Patients and Methods A total of 50 384 men diagnosed with localized PCa between 1992 and 2007 were identified within the Surveillance, Epidemiology, and End Results registry areas. We compared those who received ADT within 2 years of PCa diagnosis with those who did not, calculated as monthly equivalent doses of GnRH agonists (P < 0.001). The effect of prolonged (≥8 doses) GnRH agonist use on cardiac events was sustained across all strata of life expectancy; however, there was no effect among men with a life expectancy of P = 0.964). The use of GnRH agonists was associated with a higher risk of CHD (HR P < 0.001). Conversely, the use of GnRH was generally not associated with an increased risk of AMI or SCD, except for men who received ≥8 doses of GnRH agonists and had a life expectancy of ≥5 years, who were at a significantly higher risk of SCD (HR for life expectancy 5–10 years: 1.19, 95% CI 1.06–1.33; P = 0.003 and HR for life expectancy >10 years: 1.16, 95% CI 1.04–1.29; P = 0.006). Finally, orchiectomy was not associated with overall cardiac events, AMI or SCD, and was protective with regard to cardiac‐related interventions (HR 0.78, 95% CI 0.68–0.90, P = 0.001). Conclusion Exposure to ADT with GnRH agonists is associated with an increased risk of cardiac events in elderly men with localized PCa and a decent life expectancy. Clinicians should carefully weigh the risks and benefits of ADT in patients with a prolonged life expectancy. Routine screening and lifestyle interventions are warranted in at‐risk subpopulations treated with ADT.Keywords
Funding Information
- Vattikuti Urology Institute
- Women of the University Medical Center Hamburg-Eppendorf
This publication has 47 references indexed in Scilit:
- Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysisEuropean Urology, 2015
- The impact of androgen‐deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non‐metastatic prostate cancer: a population‐based studyBJU International, 2014
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013European Urology, 2013
- Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implicationsAnnals of Oncology, 2013
- Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developmentsBritish Journal of Cancer, 2011
- Absolute and Relative Risk of Cardiovascular Disease in Men With Prostate Cancer: Results From the Population-Based PCBaSe SwedenJournal of Clinical Oncology, 2010
- Androgen deprivation therapy for prostate cancerExpert Opinion on Pharmacotherapy, 2008
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate CancerNew England Journal of Medicine, 1999
- Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and GoserelinNew England Journal of Medicine, 1997